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Background: Although the incidence of glioma is relatively low, it is the most malignant tumor of the central
nervous system. The prognosis of high-grade glioma patient is very poor due to the difficulties in complete resection
and resistance to radio-/chemotherapy. Therefore, it is worth investigating the molecular mechanisms involved in
glioma drug resistance. MicroRNAs have been found to play important roles in tumor progression and drug resistance.
Our previous work showed that miR-181b is involved in the regulation of temozolomide resistance. In the current study,
we investigated whether miR-181b also plays a role in antagonizing the effect of teniposide.
Methods: MiR-181b expression was measured in 90 glioma patient tissues and its relationship to prognosis of these
patients was analyzed. Cell sensitivity to teniposide was tested in 48 primary cultured glioma samples. Then miR-181b
stably overexpressed U87 cells were generated. The candidate genes of miR-181b from our previous study were
reanalyzed, and the interaction between miR-181b and target gene MDM2 was confirmed by dual luciferase assay.
Cell sensitivity to teniposide was detected on miR-181b over expressed and MDM2 down regulated cells.
Results: Our data confirmed the low expression levels of miR-181b in high-grade glioma tissues, which is related to
teniposide resistance in primary cultured glioma cells. Overexpression of miR-181b increased glioma cell sensitivity to
teniposide. Through target gene prediction, we found that MDM2 is a candidate target of miR-181b. MDM2 knockdown
mimicked the sensitization effect of miR-181b. Further study revealed that miR-181b binds to the 3’-UTR region of
MDM2 leading to the decrease in MDM2 levels and subsequent increase in teniposide sensitivity. Partial restoration of
MDM2 attenuated the sensitivity enhancement by miR-181b.
Conclusions: MiR-181b is an important positive regulator on glioma cell sensitivity to teniposide. It confers glioma cell
sensitivity to teniposide through binding to the 3’-UTR region of MDM2 leading to its reduced expression. Our findings
not only reveal the novel mechanism involved in teniposide resistance, but also shed light on the optimization of
glioma treatment in the future.
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Gliomas are the most common primary brain tumors.
There are around 10,000 new cases of high-grade gliomas
each year in the United States [1]. Malignant gliomas are
currently treated by surgery followed by radiotherapy and
chemotherapy [2]. Although cancer survivors are esti-
mated to be over 13.7 million in the United States [3], the* Correspondence: chenzhp@sysucc.org.cn
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unless otherwise stated.five-year survival rate of the most malignant glioma, glio-
blastoma multiforme(GBM), is only 9.8% at the best due
to difficulties in complete resection and the low sensitivity
to radio-/chemo- therapeutic agents [4-6].Therefore, find-
ing ways to sensitize glioma cells to both radiotherapy and
chemotherapy is of great importance.
MicroRNAs (miRNAs), a class of small noncoding RNA
of 20–22 nucleotides in length, are processed from larger
pre-miRNAs by the RNase III enzyme Dicer (DICER1) into
miRNA duplexes. One strand of the duplex will then asso-
ciate with the RNA-induced silencing complex (RISC), and
the other will be degraded by nucleases. The RNA-RISC. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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to target degradation and subsequent translational silen-
cing. MiRNA regulates the expression of downstream tar-
get genes and involves in tumorigenesis as well as tumor
sensitivity to treatment [7]. There is evidence showing that
miRNA could also function as both tumor suppressors
and oncogenes. MiR-181b has been shown to be a tumor
suppressor. It functions as an inhibitor in tumor growth,
colony formation and invasion [8-10]. MiR-181b is down-
regulated in tumor tissues and glioma cell lines. It is much
lower in cancer stem cells enriched from the glioma cell
line U87. The ectopic expression of miR-181b suppressed
glioma cell colony formation, proliferation and reduced
their resistance to temozolomide [11].
Teniposide (Vumon, VM-26), a semi-synthetic derivative
of podophyllotoxin resin, is a cell cycle specific cytotoxic
drug that inhibits the activity of DNA topoisomerase-II and
stabilizes the DNA-Topo II complex in DNA replication,
thus damaging DNA and inducing cellular apoptosis. Teni-
poside has been used successfully in treating several neo-
plastic disorders, such as lung and ovarian cancers as well
as squamous cell carcinoma [12-14]. Teniposide has grad-
ually become the effective chemotherapeutic drug for intra-
cranial malignant tumors due to its low cytotoxicity, high
lipid solubility and small molecular weight, all of which fa-
cilitates its passage through the blood-brain barrier [15,16].
Although the initial response of teniposide is remarkable,
tumor resistance develops rapidly after prolonged adminis-
tration [17]. Therefore, it is of therapeutic significance to
determine how to promote drug sensitivity, and therefore
reduce application dose. In this study, we confirmed the ex-
pression of miR-181b decreases with increasing grade in
gliomas. More importantly, we demonstrated that miR-
181b promotes the sensitivity of glioma cells to teniposide
through direct modulation of the level of MDM2.
Methods
Patients and cell lines
Patient tumor samples were collected, with written in-
formed consent, from the Department of Neurosurgery/
neuro-oncology, Sun Yat-sen University Cancer Center
(SYSUCC) between 2001 and 2008. Primary tumor cul-
tures were derived from the tissue samples using the
method described by Brassesco et al. [18]. Human GBM
cell line U87 (maintained in SYSUCC) were obtained from
American Type Culture Collection. All cells were main-
tained in DMEM (Gibco) supplemented with 10% fetal bo-
vine serum (FBS, Hyclone) and 1% penicillin–streptomycin
(Gibco) at 37°C in a humidified incubator with 5% CO2.
The Ethics Review Board of SYSUCC approved this study.
Primary cell culture
Fresh tumor samples (verified from frozen sections),
aseptically collected in the operating room, were mincedwith scissors in a petri dish. The tumor pieces were then
disaggregated for 4 h at 37°C in 0.5% type IV collagenase
(Sigma-Aldrich, St Louis, MO, USA) in F10 medium
(Life Technologies, Carlsbad, CA, US). Then, the cells
were pelleted and resuspended in the medium with 15%
FBS. Cells were used for experiments after being cul-
tured for 1 week.
RNA extraction and real-time PCR analysis
RNAs from 90 glioma samples and 4 normal brain tissues
(normal adjacent tissues) were extracted with Trizol re-
agent (Invitrogen, USA) accordingly. RNA concentration
and purity were measured using the NanoDrop ND-1000
Spectrophotometer (Thermo Fisher).One μg of total RNA
was used for cDNA synthesis by the First Strand cDNA
Synthesis Kit (Thermo-scientific, PA, USA).Real-time PCR
reaction was performed as follows: 94°C 4 min for hot
start, and then 94°C for 30 sec, 50°C for 30 sec, 72°C for
40 sec, for 40 thermal cyclesusing SYBR Premix Ex Taq II
kit (TaKaRa, Dalian, China) on an ABI 7900HT instru-
ment (ABI, NY, USA). The primers for miR-181b and
U6 endogenous controls were purchased from RiboBio
(Guangzhou, China). Primers for the MDM2 and GAPDH
controls were from Invitrogen. All reactions were per-
formed in triplicates. Relative gene expression was calcu-
lated using the 2-ΔΔCT method.
Chemosensitivity assay
Cells (primary cultured cells and U87 cell line) were
seeded onto 96-well plates at 2,000 cells per well in tri-
plicates. The next day, cells were treated with teniposide
at a concentration gradient of 50, 25, 12.5, 6.25, 3.125,
1.5625, 0.78125, 0.39, 0.19, and 0 μg/ml. Cell viability was
measured after 72 h using the Cell Counting Kit 8(CCK8,
Dojindo, Japan) according to the manufacturer’s instruc-
tions. IC50 for teniposide was calculated from the dose-
dependent curve.
miR-181b lentiviral transfection
The effect of miR-181b on cell sensitivity to teniposide was
evaluated by constructing stable miR-181b-expressing gli-
oma cells. The lenti-miR-181b and the corresponding
empty vector were purchased from GenePharma (Shanghai,
China). U87 was selected due to its low basal level of miR-
181b. After being incubated with the virus for 72 h, cells
were selected by medium containing 2 μg/ml puromycin
for about 1 week.
miR-181b target gene prediction
The candidate targets of miR-181b were predicted by
the following applications: Target scan (http://www.
targetscan.org), PicTar (www.pictar.org), and database
(www.mirbase.org).
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The plasmids psiCHECK-wtMDM2 and psiCHECK-
mutMDM23’UTRs (carrying a mutational miR-181b
binding site) were purchased from Land (Guangzhou,
China). In brief, the full length MDM2 and empty psi-
CHECK vector were digested by same restriction en-
donuclease, followed with ligation, transformation, and
then confirmed by both digestion and sequencing. The
mutant MDM2 sequence was generated by mutagenesis
PCR reaction from psiCHECK-wtMDM2. Then similar
procedures (endonuclease digestion, ligation, transform-
ation and confirmation) were performed to get psiCHECK-
mutMDM2. 293 T cells were seeded onto 24-well plates.
After overnight incubation, they were co-transfected with
50 nM miR-181b mimic or non-relevant control (NC),
together with 0.5 μg reporter vector containing either
wtMDM2 3’UTR or mutMDM23’UTR. Cells were har-
vested 48 h after transfection. The renilla and firefly lucifer-
ase activity were determined byDual Luciferase Assay Kit
(Promega) following manufacturer’s instructions. Data
were presented as mean ratio of the renilla/firefly luciferase
activity obtained from at least three independent experi-
ments [19].
Western blot analysis
Cells were washed twice with ice-cold PBS and lysed in
RIPA buffer containing 1 mM PMSF (Beyotime, Japan) on
ice [20]. Lysates were centrifuged at 12,000 × g for 10 min
at 4°C, and supernatants were collected. Equal amounts of
proteins (20 μg) were fractionated by SDS-PAGEand trans-
ferred onto nitrocellulose membranes (Millipore, MA,
USA). After being blocked in 5% nonfat milk at room
temperature for 1 h, membranes were probed with primary
antibodies at 4°C overnight. The next day, secondary anti-
bodies were incubated for 1 h at room temperature and vi-
sualized using enhanced chemiluminescence (Millipore,
MA, USA). The following antibodies were used: mouse
anti-β-actin (1:1000, Santa Cruz, Dallas, TX, USA), rabbitA
Figure 1 MiR-181b expression is negatively related to glioma grade.
IV) while high in low-grade (Grade I) gliomas (**: p < 0.01). B: The survival r
prognostic marker for longer survival (p < 0.05).anti-MDM2 (1:5000, Abcam, Cambridge, MA, USA), anti-
phospho-MDM2 (1:1000, Cell signaling technologies,
Boston, MA, USA).
Statistical analysis
The correlation between miR-181b expression and patient
survival was analyzed by the Kaplan-Meier survival curve
method. The correlation between miR-181b and glioma
sensitivity to teniposide was determined by Spearman’s cor-
relation coefficient. Differences between groups were calcu-
lated using paired t-test or one-way ANOVA. p < 0.05 was
considered statistically significant. All statistical analyses
were performed using SPSS, version 16.0.
Results
Expression of miR-181b is related to poor prognosis of
glioma patients
A total of 90 glioma samples (WHO grade I to grade IV)
were included in this study. Their cDNA were subjected
to real-time PCR analysis on the expression level of
miR-181b. We found that miR-181blevel was high in
normal brain (3.69 ± 0.477) and low-grade glioma tissues
(2.56 ± 0.354 in grade I gliomas) but very low in the high
grade ones (0.067 in grade IV gliomas) (Figure 1A, p < 0.01).
The Kaplan-Meier analysis showed that the median sur-
vival of patients with high expression levels of miR-181b
was 493 ± 60 days, but only 370 ± 37 days in the low ex-
pression group (Figure 1B, p < 0.05). These data were con-
sistent with previous reports emphasizing the important
role of miR-181b in glioma progression.
MiR-181b level correlates with glioma cell sensitivity to
teniposide
Primary cultured glioma cells from 48 patients were
treated with teniposide. The data showed that cells were
highly sensitive to teniposide when expressing high levels
of miR-181b, while cells showed resistance to teniposide
when miR-181b level was low (Figure 2A). Expression ofB
A: The expression of miR-181b is low in high-grade (Grade II to Grade
ate of 90 glioma patients showed that high level of miR-181b is a good
CB
A
Figure 2 MiR-181b level is positively related to glioma cell
sensitivity to teniposide. A: Cells expressing low levels of
miR-181b had high IC50, while cells with high miR-181b had low
IC50 (r = -0.691, p < 0.01). B: MiR-181b was successfully overexpressed
in U87 cells compared with vector control (*p < 0.01). C: The IC50 of
miR-181b overexpressed U87 cells was significantly lower than
control cells (1.3 ± 0.34 μg/ml versus 6.2 ± 0.87 μg/ml).
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by real-time PCR (Figure 2B). The modified U87 cells
were subjected to teniposide treatment and cell viability
evaluated. MiR-181b overexpressed cells were more sensi-
tive to teniposide and the number of viable cells was muchlower than control cells. The IC50 was 1.3 ± 0.34 μg/ml
versus 6.2 ± 0.87 μg/ml respectively (Figure 2C). These
data demonstrated that miR-181b could promote the sen-
sitivity of glioma cells to teniposide.
MDM2 is a target of miR-181b
We were wondering how miR-181b mediating the
sensitization of glioma cells to teniposide. From well-
known databases for miRNA targets prediction, we
found that mouse double minute 2 (MDM2), an import-
ant negative regulator of the p53 tumor suppressor, is
one of the candidate targets of miR-181b. Microarray
from our group also showed that MDM2 is one of the
85 downregulated genes in glioma cells with stable over-
expression of miR-181b [19]. Consistently, we found
both mRNA and protein levels of MDM2 were dra-
matically reduced after miR-181b overexpression, and
phospho-MDM2 was decreased consequently (Figure 3A).
To further confirm the interaction between MDM2 and
miR-181b, we constructed the wild type and mutant
MDM2 for dual luciferase reporter assay (Figure 3B). As
expected, miR-181b bound to wild type of MDM2 but not
to the mutant type (Figure 3C).
Downregulation of MDM2 sensitizes glioma cells to
teniposide
Next we sought to find out whether downregulation of
MDM2 could mimic the promotion of cell sensitivity to
teniposide by miR-181b. We knocked down MDM2 by
siRNA and successfully reduced the mRNA level of
MDM2 and protein level of phospho-MDM2 signifi-
cantly (Figure 4A). After being treated with teniposide,
cells with low MDM2 showed decreased viability com-
pared with control cells, and theIC50 decreased from
5.86 ± 0.36 μg/ml to 2.90 ± 0.35 μg/ml upon MDM2 sup-
pression (Figure 4B). These data suggested that downregu-
lation of MDM2 could fully mimic the effect of miR-181b
in increasing glioma cell sensitivity to teniposide.
MiR-181b promotes glioma cell sensitivity to teniposide
through MDM2
To determine if miR-181b-enhanced glioma cell sensitivity
to teniposide was directly mediated by MDM2, we trans-
fected glioma cells with miR-181b alone or together with
mutant MDM2.Comparing with the vector control
(Figure 5A, lane 2), the phospho-MDM2 level was re-
duced when cells were transfected with miR-181b alone
(Figure 5A, lane 1). It was partially restored when co-
transfected with mutant MDM2 (Figure 5A, lane 3). As
expected, miR-181b transfection alone decreased the gli-
oma cell sensitivity to tenopiside, IC50 of 1.73 ± 0.07 μg/ml
versus 6.0 ± 0.2 μg/ml in the control cells (Figure 5B).
Partial restoration of MDM2, thus the phospho-MDM2
levels, through the co-transfection of mutant MDM2 led
AB
C
Figure 3 MDM2 is a downstream target of miR-181b. A: The mRNA level of MDM2 in miR-181b overexpressed U87 cells was reduced. The
protein levels of total MDM2 and phospho-MDM2 were all reduced in miR-181b overexpressed cells compared with vector control (p < 0.01).
B. MiR-181b could bind to the 3’-UTR region of MDM2 (3491 to 3497), while the binding was interrupted with mutated MDM2. C: Dural luciferase
reporter assay confirmed that miR-181b mimic binds to the 3’-UTR region of wild type MDM2 but not to the mutated form (p < 0.05).
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sults indicated that the level of phospho-MDM2 is respon-
sible for glioma cell sensitivity to teniposide. Thus, we
demonstrated that miR-181b enhances glioma cell sensi-
tivity to teniposide through targeting E3-ligase MDM2.BA
Figure 4 Downregulation of MDM2 promotes cell sensitivity to tenipo
were all reduced after transient transfection of siRNAs in U87 cells. B: The I
2.90 ± 0.35 μg/ml upon the knockdown of MDM2.Discussion
MiR-181b has already been investigated in a number of
cancer types. It is overexpressed in gastric cancer tissues
and its expression in culture gastric cancer cells pro-
motes cell proliferation, migration and invasion; whereasside. A: The mRNA (p < 0.01) and phosphate protein level of MDM2











Figure 5 Upregulation of miR-181b enhances cell sensitivity to teniposide through mediation of MDM2. A: Successful overexpression of
miR-181b and mutated MDM2 was confirmed by Western blot analysis. B: Transfection of mutated MDM2 competed the binding between
miR-181b and wild type of MDM2, which reversed the teniposide sensitivity enhancement by miR-181b.
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[21]. MiR-181b also involves in hepatocarcinogenesis
through promoting growth, clonogenic survival, migra-
tion and invasion of hepatocellular carcinoma cells [22].
In colorectal cancer, miR-181b is also overexpressed in
tumor tissues compared with normal colorectal samples
[23]. Although overexpression of miR-181b has been re-
ported in several malignant cancers, its level in glioma is
unexpectedly low. Zhi et al. found that low level of miR-
181b expression in glioma tissues, through screening the
miRNA expression profile of 84 astrocytomas and 20
normal adjacent tissues, is associated with poor patient
survival [24]. They further validated their findings in an-
other sample set with 40-paired astrocytoma and normal
adjacent tissues. From immunohistochemistry and in
situ hybridization assays, Tao et al. found that miR-181b
is expressed at a lower level in high-grade glioma, com-
pared with low-grade glioma [25]. The data from this
study added support to previous findings where miR-
181b expression is inversely related to the grading of gli-
oma, and the expression level is a good indication of
prognosis.
MiR-181b has also been reported to play roles in drug
resistance in various cancers. It was found to be associ-
ated with the strong response to S-1 (the fourth gener-
ation product of 5-fluoroufacil) when expressed low,
which provided evidence for the clinical application of
miR-181b as an indicator for chemoresponse of S-1 [26].
Enforced overexpression of miR-181b sensitized the hu-
man multidrug resistant cell lines SGC7901/vincristine
(gastric cancer) and A549/cisplatin (lung cancer) to vin-
cristine and cisplatin respectively [27]. Our study dem-
onstrated that low levels of miR-181b are related to the
high resistance to teniposide in primary glioma cells. By
contrast, enforced expression of miR-181b in the glioma
cell line U87 promoted teniposide sensitivity.
MiR-181b expression level was found to be signifi-
cantly lower in poor prognostic chronic lymphocyticleukemia (CLL) patients [28]. Further study showed that
transfection of miR-181b mimics could induce apoptosis
in CLL cells with wild type p53, but had no effect in p53
attenuated cells [29]. Thus, the role of miR-181b in
apoptosis and drug response is related to the p53 status.
The link between miR-181b and p53 is now provided by
the data in our study. Through overexpression of miR-
181b, siRNA knockdown of MDM2 and partial restor-
ation of functional MDM2, we have shown that the ef-
fect of miR-181b is via the phosphorylation of MDM2.
The latter is a critical E3-ligase to suppress p53 protein
level through ubiquitination-mediated degradation [30].
The direct effect of miR-181b on MDM2 could further
lead to the reversion of p53 degradation mediated by
MDM2. Taken together, miR-181b turns out not only to
be a very important microRNA in carcinogenesis, but
also plays a critical role in regulating drug sensitivity.
Our finding may shed light on how to reduce the side ef-
fect and enhance the cell sensitivity of teniposide in
treating glioma patients.
Conclusions
MiR-181b is expressed at low levels in high-grade gli-
omas and can be used as a prognostic marker for glioma
patients. Low level of miR-181b is related to teniposide
resistance mediated through MDM2.
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